Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders

CNS Drugs

Volumn 19, Issue 11, 2005, Pages 923-934

  Malone, Richard P ^a   Gratz, Silvia S ^a   Delaney, Mary Anne ^a   Hyman, Susan B ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; DESIPRAMINE; DEXAMPHETAMINE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LEVODOPA; LIOTHYRONINE; MAGNESIUM; METHYLPHENIDATE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE ANTAGONIST; OXYTOCIN; PIMOZIDE; PYRIDOXINE; QUETIAPINE; RISPERIDONE; SECRETIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANGER; ANOREXIA; ANXIETY; ASPERGER SYNDROME; AUTISM; BACKACHE; CHILD; CLINICAL TRIAL; COMPULSION; CONSTIPATION; CRYING; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; ECG ABNORMALITY; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLUSHING; GLUTEN FREE DIET; GRAND MAL EPILEPSY; HEADACHE; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LOW DRUG DOSE; MENTAL INSTABILITY; NAUSEA; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL WITHDRAWAL; QT PROLONGATION; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SKIN TINGLING; STEREOTYPY; STOMACH PAIN; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TACHYCARDIA; URINE RETENTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; NALTREXONE; NUTRITION THERAPY; SEROTONIN UPTAKE INHIBITORS; VITAMINS;

EID: 27644556217     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519110-00003     Document Type: Review

References (94)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347 (5): 314-21
3. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19 (2): 227-39
4. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141 (10): 1195-202
5. Naruse H, Nagahata M, Nakane Y, et al. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48 (4): 173-84
6. Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 1980; 19 (4): 665-77
7. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978; 17 (4): 640-55
8. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30 (3): 582-9
9. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30 (5): 427-35
10. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000; 30 (3): 245-55
11. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25 (3): 283-94
12. Campbell M, Small AM, Collins P, et al. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 1976; 19 (1): 70-86
13. Campbell M, Fish B, Raphael D, et al. Response to triiodothyro-nine and dextroamphetamine: a study of pre-school schizophrenic children. J Autism Child Schizophr 1972; 2 (4): 343-58
14. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53 (3): 77-82
15. Jaselskis CA, Cook Jr EH, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12 (5): 322-7
16. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39 (12): 1023-31
17. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: a double-blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995; 34 (2): 223-31
18. Bouvard MR, Peboyer M, Launay JM, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 1995; 58: 191-201
19. Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Psychiatry 1993; 32 (6): 1283-91
20. Unis AS, Munson JA, Rogers SJ, et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. J Am Acad Child Adolesc Psychiatry 2002; 41 (11): 1315-21
21. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 2001; 107 (5): E71. Available from URL: http://www.pediatrics.org/cgi/content/ full/107/5/e71 [Accessed 2005 Sep 28]
22. Owley T, McMahon W, Cook EH, et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 2001; 40 (11): 1293-9
23. Coniglio SJ, Lewis JD, Lang C, et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 2001; 138 (5): 649-55
24. Sandler AD, Sutton KA, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999; 341 (24): 1801-6
25. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28 (1): 87-92
26. Campbell M, Schopler E, Cueva JE, et al. Treatment of autistic disorder. Am J Psychiatry 1996; 35 (2): 134-43
27. Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36 (6): 835-43
28. Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50 (2): 171-4
29. Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities [letter]. J Child Adolesc Psychopharmacol 1996; 6 (1): 79-80
30. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33 (1): 155-9
31. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6 (3): 177-90
32. Hardan A, Johnson K, Johnson C, et al. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1551-6
33. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27 (3): 313-23
34. Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001; 40 (10): 1206-14
35. Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002; 41 (2): 140-7
36. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 685-93
37. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37 (4): 372-6
38. Perry R, Pataki C, Munoz-Silva DM, et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997; 7 (3): 167-79
39. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6): 825-35
40. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13 (1): 25-40
41. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85 (4): 295-305
42. Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004; 161 (5): 918-20
43. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40 (8): 887-94
44. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11): 1686-96
45. Malone RP, Delaney MA, Gifford C. Ziprasidone treatment-associated changes in QTc and weight in adolescents with autism. 50th Annual Meeting of the American Academy of Child & Adolescent Psychiatry Scientific Proceedings; 2003 Oct 14-19; Washington, DC: AACAP 2003: 154
46. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41 (8): 921-7
47. Federal Drug Administration. Psychopharmacological Drugs Advisory Committee; 2000 Jul 19. Briefing document for zeldox capsules (Ziprasidone HCL) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3619b1a.pdf [Accessed 2005 Oct 3]
48. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24 (1): 62-9
49. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9 (2): 99-107
50. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14 (2): 287-94
51. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001; 26 (4): 340-1
52. Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153 (5): 738
53. Deykin EY, MacMahon B. The incidence of seizures among children with autistic symptoms. Am J Psychiatry 1979; 136 (10): 1310-2
54. Rutter M, Greenfeld D, Lockyer L. A five to fifteen year follow-up study of infantile psychosis: II. social and behavioural outcome. Br J Psychiatry 1967; 113 (504): 1183-99
55. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50 (6): 441-7
56. Sanchez LE, Campbell M, Small AM, et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35 (4): 537-44
57. Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled crossover study. J Clin Psychopharmacol 2001; 21 (4): 440-4
58. Cook Jr EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31 (4): 739-45
59. Fatemi SH, Realmuto GM, Khan L, et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28 (4): 303-7
60. DeLong RG, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002; 44 (10): 652-9
61. Courturier JL, Nicholson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2002; 12 (3): 243-8
62. Namerow LB, Thomas P, Bostic JQ, et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24 (2): 104-8
63. Hollander E, Kaplan A, Cartwright C, et al. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 2000; 15 (2): 132-5
64. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53 (11): 1001-8
65. Federal Drug Administration. FDA Talk Paper; 2003 Jun 19. FDA statement regarding the anti-depressant Paxil for pediatric population [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01230.html [Accessed 2005 Oct 3]
66. Federal Drug Administration. Available from URL: http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004_4065b1/htn [Accessed 2005 Oct 3]
67. Campbell M, Overall JE, Small AM, et al. Naltrexone in autistic children: an acute dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989; 28 (2): 200-6
68. Gillberg C, Terenius L, Lonnerholm G. Endorphin activity in childhood psychosis: spinal fluid levels in 24 cases. Arch Gen Psychiatry 1985; 42 (8): 780-3
69. Panksepp J, Sahley TL. Possible brain opioid involvement in disrupted social intent and language development in autism. In: Schopler E, Mesibov GB, editors. Neurobiological issues in autism. New York: Plenum, 1987: 357-72
70. Leboyer M, Bouvard MP, Launay JM, et al. Brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992; 22 (2): 309-19
71. Campbell M, Harris JC. Resolved: autistic children should have a trial of naltrexone. J Am Acad Child Adolesc Psychiatry 1996; 35 (2): 246-9
72. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52 (9): 766-73
73. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158 (7): 1067-74
74. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58 (4): 527-36
75. McQueen JM, Heck AM. Secretin for the treatment of autism. Ann Pharmacother 2002; 36 (2): 305-11
76. Phase 3 study for autism fails to meet dual primary endpoints. Development of secretin for schizophrenia to continue. Repligen [information release]. Waltham (MA): 2004 Jan 5
77. McEvoy GK, editor. AHFS drug information. Bethesda (MD): American Society of Health System Pharmacists Inc, 1999
78. Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9 (1): 9-15
79. Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000; 30 (2): 87-94
80. Corbett B, Khan K, Czapansky-Beilman D, et al. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism. Clin Pediatr 2001; 40 (6): 327-31
81. Carey T, Ratliff-Schaub K, Funk J, et al. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. J Autism Dev Disord 2002; 32 (3): 161-7
82. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002; 12 (3): 237-41
83. Insel TR, O'Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry 1999; 45 (2): 145-57
84. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003; 28 (1): 193-8
85. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry 1978; 135 (4): 472-5
86. Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine and magnesium on autistic symptoms: initial observations. J Autism Dev Disord 1981; 11 (2): 219-30
87. Martineau J, Barthelemy C, Garreau B, et al. Vitamin B6, magnesium, and combined B6- Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985; 20 (5): 467-78
88. Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997: 27 (4) 467-78
89. Tolbert L, Haigler T, Waits MM, et al. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord 1993; 23 (1): 193-9
90. Pfeiffer SI, Norton J, Nelson L, et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord 1995; 25 (5): 481-93
91. Rimland B. Critique of "Efficacy of vitamin B6 and magnesium in the treatment of autism". J Autism Dev Disord 1998; 28 (6): 580-1
92. Knivsberg AM, Wiig K, Lind G, et al. Dietary intervention in autistic syndromes. Developmental Brain Dysfunction 1990; 3: 315-27
93. Reichelt KL, Knivsberg AM, Nodland M, et al. Nature and consequences of hyperpeptiduria and bovine casomorphins found in autistic syndromes. Developmental Brain Dysfunction 1994; 7: 71-85
94. Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002; 5 (4): 251-61